SCHEMBL20202118

SCHEMBL20202118

O=C(c1ccnc(-c2cnn3ccc(-c4ccccc4)nc23)c1)N1C2CCCC1CNCC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMKK1 Q8N5S9 1/20 0.46
CAMKK2 Q96RR4 1/20 0.46
PIK3CD O00329 2/20 0.43
CAMK2D Q13557 8/20 0.41
KDM2B Q8NHM5 1/20 0.41
PCSK9 Q8NBP7 5/20 0.40
EGFR P00533 2/20 0.39
KCNH2 Q12809 5/20 0.39
RPLP1 P05386 1/20 0.39
RPLP0 P05388 1/20 0.39
RPS17 P08708 1/20 0.39
RPSA P08865 1/20 0.39
RPS2 P15880 1/20 0.39
RPL35A P18077 1/20 0.39
RPL7 P18124 1/20 0.39
RPL17 P18621 1/20 0.39
RPS4Y1 P22090 1/20 0.39
RPS3 P23396 1/20 0.39
RPS12 P25398 1/20 0.39
RPL13 P26373 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20186396 1.00 CAMKK1 (0.46) CAMKK1CAMKK2PIK3CDCAMK2DKDM2B
SCHEMBL20186428 0.85 CAMKK1 (0.45) CAMKK1CAMKK2PIK3CDCAMK2DPCSK9
SCHEMBL20186323 0.85 CAMKK1 (0.45) CAMKK1CAMKK2PIK3CDCAMK2DPCSK9
SCHEMBL20186369 0.84 CAMK2D (0.55) CAMK2DKCNH2
SCHEMBL20202115 0.84 CAMK2D (0.55) CAMK2DKCNH2
SCHEMBL20186034 0.83 CAMKK1 (0.47) CAMKK1CAMKK2PIK3CDCAMK2DEGFR
SCHEMBL20202117 0.83 CAMKK1 (0.47) CAMKK1CAMKK2PIK3CDCAMK2DEGFR
SCHEMBL20186839 0.82 PIK3CD (0.44) CAMKK1CAMKK2PIK3CDCAMK2DKDM2B
SCHEMBL22923460 0.81 CAMKK1 (0.45) CAMKK1CAMKK2PIK3CDCAMK2DEGFR
SCHEMBL20202162 0.79 CAMK2D (0.47) CAMKK1CAMKK2PIK3CDCAMK2DKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3548495-B1 PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS GILEAD SCIENCES INC (US) 2021-01-27 EP disclosed
WO-2018102384-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2018-06-07 WO disclosed
US-20180148457-A1 FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS GILEAD SCIENCES, INC. 2018-05-31 US disclosed
US-20180148457-A1 FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS GILEAD SCIENCES, INC. 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148457-A1 FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS CAMK1, CAMKK1, CAMK1D CAMKK1 2/4885CAMKK2 8/4885PIK3CD 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.